Published: 2018-03-21

Patients characteristics associated with better glycemic response to teneligliptin and metformin therapy in type 2 diabetes: a retrospective study

Pradeep V. Gadge, Roshani P. Gadge, Nikita D. Paralkar


Background: Teneligliptin was recently approved for type 2 diabetes (T2D) management in India and is used as monotherapy or in combination with different antidiabetic drugs. The aim of this study was to identify patients’ characteristics associated with better glycemic response to teneligliptin and metformin.

Methods: A retrospective analysis of data was performed in patients of T2D with HbA1c above 7% who were treated with teneligliptin 20 mg/d as add on to metformin (500-100 mg/d) and whose follow-up data at 12-weeks was available. Fasting blood sugar (FBS) and post-prandial blood sugar (PPBS) changes were analysed.  

Results: Among 66 patients included in analysis, mean age was 61.0±9.8 years and 53% were females. Median duration of diabetes was 2 years. At 12-weeks, a significant reduction PPBS was observed (mean change: -14.3 mg/dL, p=0.009) but not in FBS (mean change: -2.4 mg/dL, p=0.353). Among different patients’ characteristics, age ≤60 years (p=0.006), duration of ≤1 year (p=0.023), body-mass index ≥25 kg/m2 (p=0.009), presence of dyslipidemia (p=0.05) and absence of complications (p=0.012) were associated with significant reduction in PPBS but not in FBS.

Conclusions: A younger, newly-diagnosed, obese T2D patients with dyslipidemia without any complications of diabetes can derive better therapeutic effectiveness from teneligliptin added to metformin. These findings need to be confirmed in large, prospective, long duration study.



DPP4 inhibitors, FBS, India, PPBS, Teneligliptin; Type 2 diabetes

Full Text:



International Diabetes Federation Diabetes Atlas. 7th Edition 2015. 144 p. Available from Accessed 12 Jan 2018.

Simpson SH, Lin M, Eurich DT. Medication Adherence Affects Risk of New Diabetes Complications: A Cohort Study. Ann Pharmacother 2016;50:741-46.

Giugliano D, Maiorino MI, Bellastella G, Esposito K. Glycemic control in type 2 diabetes: from medication nonadherence to residual vascular risk. Endocrine. 2018;10:1-5.

Langley AK, Suffoletta TJ, Jennings HR. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy: J Human Pharmacol Drug Ther. 2007;1:27(8):1163-80..

American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2017; 40:S64-S74.

List of approved drug from 01-01-2015 to 31-01-2015. Last updated on 24/01/2018. Available from Accessed 27 January 2018.

Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: A 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes. Metab. 2012;14:1040–6.

Kadowaki T, Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes. Metab 2013;15:810–8.

Kutoh E, Hirate M, Ikeno Y. Teneligliptin As an Initial Therapy for Newly Diagnosed, Drug Naive Subjects With Type 2 Diabetes. J Clin Med Res 2014;6:287–94.

Kim MK, Rhee E-J, Han KA, Woo AC, Lee M-K, Ku BJ, et al. Efficacy and safety of teneligliptin , a dipeptidyl peptidase-4 inhibitor , combined with metformin in Korean patients with type 2 diabetes mellitus : a 16-week , randomized , double-blind , placebo-controlled phase III trial. Diabetes, Obes. Metab 2015;17:309-12.

Kadowaki T, Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension. Diabetes, Obes. Metab 2010;21(2):262–8.

Kadowaki T, Kondo K. Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig 2013;4:576–84.

Tanaka S, Suzuki K, Aoki C, Niitani M, Kato K, Tomotsune T, et al. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy. Diabetes Technol Ther 2014;16:1–6.

Unnikrishnan R, Anjana RM, Mohan V. Diabetes in South Asians: Is the phenotype different? Diabetes 2014;63:53-5.

Goda M, Kadowaki T. Teneligliptin for the treatment of type 2 diabetes. Drugs of Today 2013;49:615-29.

Sagara M, Suzuki K, Aoki C, Tanaka S, Taguchi I, Inoue T, et al. Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study. Cardiovasc Diabetol 2016;15:76.

Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: A systematic review and meta-analysis. Diabetologia 2013;56:696-708.